Theriva Biologics Stock (NYSE:TOVX)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.68

52W Range

$1.24 - $17.00

50D Avg

$4.02

200D Avg

$8.40

Market Cap

$3.70M

Avg Vol (3M)

$1.90M

Beta

1.35

Div Yield

-

TOVX Company Profile


Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

22

IPO Date

Dec 18, 2006

Website

TOVX Performance


TOVX Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-22.09M$-21.58M$-14.27M
Net Income$-18.35M$-19.68M$-14.17M
EBITDA$-21.96M$-21.45M$-14.27M
Basic EPS$-1.14$-1.28$-1.16
Diluted EPS$-1.14$-1.28$-1.16

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 23Mar 25, 24 | 12:01 PM
Q3 23Nov 17, 23 | 12:51 PM
Q2 23Aug 12, 23 | 1:52 PM

Peer Comparison


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
GOVXGeoVax Labs, Inc.
PMVPPMV Pharmaceuticals, Inc.
FRTXFresh Tracks Therapeutics, Inc.
XCURExicure, Inc.
LSTALisata Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
VRPXVirpax Pharmaceuticals, Inc.
MRKRMarker Therapeutics, Inc.
REVBRevelation Biosciences, Inc.
DFFNCervoMed Inc.
FWBIEntero Therapeutics, Inc.
VCNXVaccinex, Inc.
AVTXAvalo Therapeutics, Inc.
PRAXPraxis Precision Medicines, Inc.
SLRXSalarius Pharmaceuticals, Inc.
PTIXProtagenic Therapeutics, Inc.
CBIOGyre Therapeutics, Inc.
LUMOLumos Pharma, Inc.
KTRAKintara Therapeutics, Inc.